Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) — Analysis Summary
Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) has a market cap of $434.59M with year-over-year revenue growth of -46.1%. Net margin stands at -80.2%. The stock trades at a P/E ratio of -4.7.
Key Takeaways
- Revenue changed -46.1% year-over-year
- Net margin of -80.2%
- P/E ratio of -4.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ARCT posted revenue growth of -46.1% and trades at a P/E of -4.7.
Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -348.3% — severe operating losses
Net margin at -317.6% — losses exceed revenue (possible one-time charges)
Revenue fell 64.2% vs the prior period.
Net income fell 41.8% vs the prior period.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
111
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.